Dried blood spot sampling of nilotinib in patients with chronic myeloid leukaemia: a comparison with venous blood sampling

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Objectives: To compare nilotinib concentrations obtained by venous blood sampling and dried blood spot (DBS) in patients with chronic myeloid leukaemia (CML). It was investigated how to predict nilotinib plasma levels on the basis of DBS. Methods: Forty duplicate DBS and venous blood samples were collected from 20 patients. Capillary blood was obtained by finger prick and spotted on DMPK-C Whatman sampling paper, simultaneously with venous blood sampling. Plasma concentrations were predicted from DBS concentrations using three methods: (1) individual and (2) mean haematocrit correction and (3) the bias between plasma and DBS concentrations. Results were compared using Deming regression and Bland–Altman analysis. Key findings: Nilotinib plasma concentrations ranged from 376 to 2663 μg/l. DBS concentrations ranged from 144 to 1518 μg/l. The slope was 0.56 (95% CI, 0.51 to 0.61) with an intercept of −41.68 μg/l (95% CI, −93.78 to 10.42). Mean differences between calculated and measured plasma concentrations were −14.3% (method 1), −14.0% (method 2) and −0.6% (method 3); differences were within 20% of the mean in 73%, 85% and 80% of the samples, respectively. The slopes were respectively 0.96 (95% CI, 0.86 to 1.06), 0.95 (95% CI, 0.86 to 1.03) and 1.00 (95% CI, 0.91 to 1.09). Conclusions: Plasma concentrations of nilotinib could be predicted on the basis of DBS. DBS sampling to assess nilotinib concentrations in CML patients seems a suitable alternative for venous sampling.

Original languageEnglish
Pages (from-to)1265-1274
Number of pages10
JournalJournal of Pharmacy and Pharmacology
Volume69
Issue number10
DOIs
Publication statusPublished - 1 Oct 2017

Cite this

@article{f48a07dbe8664c388a0550ba2a39e234,
title = "Dried blood spot sampling of nilotinib in patients with chronic myeloid leukaemia: a comparison with venous blood sampling",
abstract = "Objectives: To compare nilotinib concentrations obtained by venous blood sampling and dried blood spot (DBS) in patients with chronic myeloid leukaemia (CML). It was investigated how to predict nilotinib plasma levels on the basis of DBS. Methods: Forty duplicate DBS and venous blood samples were collected from 20 patients. Capillary blood was obtained by finger prick and spotted on DMPK-C Whatman sampling paper, simultaneously with venous blood sampling. Plasma concentrations were predicted from DBS concentrations using three methods: (1) individual and (2) mean haematocrit correction and (3) the bias between plasma and DBS concentrations. Results were compared using Deming regression and Bland–Altman analysis. Key findings: Nilotinib plasma concentrations ranged from 376 to 2663 μg/l. DBS concentrations ranged from 144 to 1518 μg/l. The slope was 0.56 (95{\%} CI, 0.51 to 0.61) with an intercept of −41.68 μg/l (95{\%} CI, −93.78 to 10.42). Mean differences between calculated and measured plasma concentrations were −14.3{\%} (method 1), −14.0{\%} (method 2) and −0.6{\%} (method 3); differences were within 20{\%} of the mean in 73{\%}, 85{\%} and 80{\%} of the samples, respectively. The slopes were respectively 0.96 (95{\%} CI, 0.86 to 1.06), 0.95 (95{\%} CI, 0.86 to 1.03) and 1.00 (95{\%} CI, 0.91 to 1.09). Conclusions: Plasma concentrations of nilotinib could be predicted on the basis of DBS. DBS sampling to assess nilotinib concentrations in CML patients seems a suitable alternative for venous sampling.",
keywords = "chronic myeloid leukaemia, dried blood spot, nilotinib, therapeutic drug monitoring",
author = "Boons, {Christel C.L.M.} and Abdel Chahbouni and Schimmel, {Anneliene M.} and Wilhelm, {Abraham J.} and {den Hartog}, {Yvonne M.} and Janssen, {Jeroen J.W.M.} and Hendrikse, {N. Harry} and Hugtenburg, {Jacqueline G.} and Swart, {Eleonora L.}",
year = "2017",
month = "10",
day = "1",
doi = "10.1111/jphp.12757",
language = "English",
volume = "69",
pages = "1265--1274",
journal = "Journal of Pharmacy and Pharmacology",
issn = "0022-3573",
publisher = "Wiley-Blackwell",
number = "10",

}

Dried blood spot sampling of nilotinib in patients with chronic myeloid leukaemia : a comparison with venous blood sampling. / Boons, Christel C.L.M.; Chahbouni, Abdel; Schimmel, Anneliene M.; Wilhelm, Abraham J.; den Hartog, Yvonne M.; Janssen, Jeroen J.W.M.; Hendrikse, N. Harry; Hugtenburg, Jacqueline G.; Swart, Eleonora L.

In: Journal of Pharmacy and Pharmacology, Vol. 69, No. 10, 01.10.2017, p. 1265-1274.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Dried blood spot sampling of nilotinib in patients with chronic myeloid leukaemia

T2 - a comparison with venous blood sampling

AU - Boons, Christel C.L.M.

AU - Chahbouni, Abdel

AU - Schimmel, Anneliene M.

AU - Wilhelm, Abraham J.

AU - den Hartog, Yvonne M.

AU - Janssen, Jeroen J.W.M.

AU - Hendrikse, N. Harry

AU - Hugtenburg, Jacqueline G.

AU - Swart, Eleonora L.

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Objectives: To compare nilotinib concentrations obtained by venous blood sampling and dried blood spot (DBS) in patients with chronic myeloid leukaemia (CML). It was investigated how to predict nilotinib plasma levels on the basis of DBS. Methods: Forty duplicate DBS and venous blood samples were collected from 20 patients. Capillary blood was obtained by finger prick and spotted on DMPK-C Whatman sampling paper, simultaneously with venous blood sampling. Plasma concentrations were predicted from DBS concentrations using three methods: (1) individual and (2) mean haematocrit correction and (3) the bias between plasma and DBS concentrations. Results were compared using Deming regression and Bland–Altman analysis. Key findings: Nilotinib plasma concentrations ranged from 376 to 2663 μg/l. DBS concentrations ranged from 144 to 1518 μg/l. The slope was 0.56 (95% CI, 0.51 to 0.61) with an intercept of −41.68 μg/l (95% CI, −93.78 to 10.42). Mean differences between calculated and measured plasma concentrations were −14.3% (method 1), −14.0% (method 2) and −0.6% (method 3); differences were within 20% of the mean in 73%, 85% and 80% of the samples, respectively. The slopes were respectively 0.96 (95% CI, 0.86 to 1.06), 0.95 (95% CI, 0.86 to 1.03) and 1.00 (95% CI, 0.91 to 1.09). Conclusions: Plasma concentrations of nilotinib could be predicted on the basis of DBS. DBS sampling to assess nilotinib concentrations in CML patients seems a suitable alternative for venous sampling.

AB - Objectives: To compare nilotinib concentrations obtained by venous blood sampling and dried blood spot (DBS) in patients with chronic myeloid leukaemia (CML). It was investigated how to predict nilotinib plasma levels on the basis of DBS. Methods: Forty duplicate DBS and venous blood samples were collected from 20 patients. Capillary blood was obtained by finger prick and spotted on DMPK-C Whatman sampling paper, simultaneously with venous blood sampling. Plasma concentrations were predicted from DBS concentrations using three methods: (1) individual and (2) mean haematocrit correction and (3) the bias between plasma and DBS concentrations. Results were compared using Deming regression and Bland–Altman analysis. Key findings: Nilotinib plasma concentrations ranged from 376 to 2663 μg/l. DBS concentrations ranged from 144 to 1518 μg/l. The slope was 0.56 (95% CI, 0.51 to 0.61) with an intercept of −41.68 μg/l (95% CI, −93.78 to 10.42). Mean differences between calculated and measured plasma concentrations were −14.3% (method 1), −14.0% (method 2) and −0.6% (method 3); differences were within 20% of the mean in 73%, 85% and 80% of the samples, respectively. The slopes were respectively 0.96 (95% CI, 0.86 to 1.06), 0.95 (95% CI, 0.86 to 1.03) and 1.00 (95% CI, 0.91 to 1.09). Conclusions: Plasma concentrations of nilotinib could be predicted on the basis of DBS. DBS sampling to assess nilotinib concentrations in CML patients seems a suitable alternative for venous sampling.

KW - chronic myeloid leukaemia

KW - dried blood spot

KW - nilotinib

KW - therapeutic drug monitoring

UR - http://www.scopus.com/inward/record.url?scp=85021263147&partnerID=8YFLogxK

U2 - 10.1111/jphp.12757

DO - 10.1111/jphp.12757

M3 - Article

VL - 69

SP - 1265

EP - 1274

JO - Journal of Pharmacy and Pharmacology

JF - Journal of Pharmacy and Pharmacology

SN - 0022-3573

IS - 10

ER -